TBPN Live - Novartis Buys Excellergy for $2B, Anthropic Vs. Pentagon, The Mansion Section | Diet TBPN

Episode Date: March 28, 2026

Diet TBPN delivers the best of today’s TBPN episode in 30 minutes. TBPN is a live tech talk show hosted by John Coogan and Jordi Hays, streaming weekdays 11–2 PT on X and YouTube, with each episode posted to podcast platforms right after.Described by The New York Times as “Silicon Valley’s newest obsession,” the show has recently featured Mark Zuckerberg, Sam Altman, Mark Cuban, and Satya Nadella.TBPN is made possible by:Ramp - https://Ramp.comAppLovin - https://axon.aiCisco - https://www.cisco.comCognition - https://cognition.aiConsole - https://console.comCrowdStrike - https://crowdstrike.comElevenLabs - https://elevenlabs.ioFigma - https://figma.comFin - https://fin.aiGemini - https://gemini.google.comGraphite - https://graphite.comGusto - https://gusto.com/tbpnKalshi - https://kalshi.comLabelbox - https://labelbox.comLambda - https://lambda.aiLinear - https://linear.appMongoDB - https://mongodb.comNYSE - https://nyse.comOkta - https://www.okta.comPhantom - https://phantom.com/cashPlaid - https://plaid.comPublic - https://public.comRailway - https://railway.comRestream - https://restream.ioSentry - https://sentry.ioShopify - https://shopify.com/tbpnTurbopuffer - https://turbopuffer.comVanta - https://vanta.comVibe - https://vibe.coFollow TBPN: https://TBPN.comhttps://x.com/tbpnhttps://open.spotify.com/show/2L6WMqY3GUPCGBD0dX6p00?si=674252d53acf4231https://podcasts.apple.com/us/podcast/technology-brothers/id1772360235https://www.youtube.com/@TBPNLive

So why is no one talking about Accelergy? I love these titles. Very niche company. It was in stealth mode for five years, but sold this week to Novartis for two billion smackaroos. That's a good outcome. Novartis, of course, is the $300 billion Swiss pharmaceutical company, and they just paid $2 billion for basically a five-year-old company named Accelergy.

Is that good? It's a great outcome. This is an interesting story because it's very much like the biotech playbook done right. They bring in the right CEO. You just, Tyler. Tyler, is a $2 billion exit in five years from your point of view. Is this good? Is this good?

That's pretty good, yeah. I agree. It's, but this isn't in the sweet spot for typical tech news, but there are some interesting, there are some interesting data points. Amir over at the information said, leading indicator of AI adoption, drug companies like Novo Nardis, pharma has long been at the forefront of machine learning. Makeer says AI agents are shortening its clinical trials. People think that it's going to a prompt and saying like, cure cancer, it's not. It's like you have a 10,000 page document that you need to

send to the FDA. And if there's a comma in the wrong place, they can just send it back to you and say, there's an air. Like, we don't want to deal with it right now. You're back at the back of the is that real? You can get dinged for crazy, crazy stuff. Like I don't know exactly what I can share, but I've heard of multi-billion dollar companies getting dinged for not showing. Like, they will list out, okay, we use this centrifuge to run this assay, to understand how this chemical separates. But they didn't say they didn't list out who the suppliers to that supplier are. They didn't explain the entire supply chain.

And there was like very little guidance on it. Like little things like that come up all the time and reading through all the documentation. Of course, most of this when you're talking about Nova, it's like they have a direct line of communication with the FDA. So it's different. When some type of public company software CEO comes out and says like everything is accelerating because of AI, oftentimes I look at the business and if, you know, if revenue isn't accelerating dramatically, you think like, okay, this guy just wants an AI narrative.

He's just reaching for an AI narrative here. But when I see a farmer company do it, no real context on on pharma personally. It must be true. Yeah. I mean, I was working on FDA filing as like four or five. years ago and there were so many word documents that needed to be part it was the same application for multiple variations on the product that the FDA was going to review and so we actually wrote python scripts to programmatically interact with the word documents to to basically do like a very advanced

version of find and replace it's like perfect for AI yeah and it just speeds things up a little bit you submit a week earlier you have you know you can submit more things more variations you can give more information, compile more information, investigate other literature, do deep research reports, what else is out there? Let's review all the IP faster, summarize things, find different threads to pull on. Little things like that just squeak out, like an extra five minutes here, an extra day there, and it all adds up to acceleration and progress. It's not like an overnight, all of a sudden everything's completely changed. Maybe that happens. But at least right now, there's clearly, you know, a benefit from this.

But this was an overnight success, at least for Alex Egel, Ted Jardensky, Luke Pennington, and Jeff Harris, who took academic research, which they've been doing at labs at Stanford and Byrne, into what is basically a VC-backed biotech company, a drug company. So the goal was simple. What do they actually make? They wanted to make a better allergy drug. So when people have allergies, they, you know, you have a peanut allergy. If peanuts come in, your allergy cells like flare up and you need to fight that back.

So the current blockbuster drug in the category is called Zolayer. And when someone has an allergic reaction to a food, allergy drugs act quickly to treat the reaction before it does lasting damage to the body. So the key immune molecule at the center of many allergic reactions is called IGE. And XLRG's lead program, EXL-111, targets IGE. So the goal is to work faster, quiet the pathway more deeply, and ideally last longer between doses to fight allergic reactions. And so these will make that less severe. So Red Tree Venture Capital ceded the company in 2021, but they stayed in stealth for about five years. The team announced their first big fundraise, a $70 million series A, led by Samsara Bio Capital.

This is a pretty typical flow for biotech companies. University of Science first, then they bring on secondary specialist capital, someone with experience in biotech. It's less common to go to like the big names that we know, the Sequoias, the founders funds, the Andresans. They do some stuff in bio, but very often, if it's coming directly out of a lab, going to be IPOed or acquired in a few years, like that's a pretty traditional biotech VC playbook. And so by February of this year, Accelergy dosed its first phase one patients. So they gave the drug to subjects. And it was obviously looking good because the Novartis deal signed a few weeks.

Yeah, how well does that phase one trial need to go for somebody to immediately come in and be like, yep, here's two billion? Probably really well. But it is like standing on the shoulders of giants. Remember, the research was done in 2020, 2021, probably earlier than that. And it's building on an existing pathway. There's some interesting stuff going on. So Novartis. This guy is such.

The CEO is such a chat. Yeah. Insane. So, yeah, I was like, I didn't want to diminish his accomplishments by reducing it to a playbook. But this isn't his first rodeo. The CEO, Todd Zavoddnick, Zavodnick. He joined in 2025, sells the company in less than a year. And he's seen the story twice before.

When he was at Zeltic, Allergan acquired it for $2.4 billion. And when he ran Dermavant, he sold that company for $1.2 billion in 2024. So he's seen a unicorn outcome two years ago, and he gets a new job. He says, I was going to take some time off, gets back in the arena, and immediately sells the company. So clearly a great operator. And no one was really surprised by this, at least in the stock market. Here's a flat.

next company. That's a good idea. Just follow this guy around. Just $3 billion acquisitions back to back. I would, I think it's a good risk-adjusted. I would love to be a janitor here.

I'll actually take all stock. I'll take all stock and I will clean the toilets and get coffee if that's what it takes. I know what's going to happen. I've seen this playbook before. Anyway, Novartis, you know, the stock is not really moving on this news because this is very expected.

This is part of their playbook. last year, 2025, they made $1.7 billion in sales of Zolair, the allergy drug that's currently the blockbuster drug in the category. And this is a very logical next act in that category. So key Zolair patents are about to expire. So a next generation IGE asset is strategically valuable right now. Novartis's CEO has previously outlined a pretty broad acquisition playbook. It's focused on bolt-on deals in core areas. So when they have a business up and running like immunology, like treating allergies. They have all of the sales and distribution.

They have an existing product portfolio. The business is working. Add things on to extend the viability of that business line. And AccelerG fits squarely inside of that plan. Now, the $2 billion acquisition price, it's not all cash upfront. It is split between an upfront payment and there's milestones based on development

and commercial targets. So if they succeed, all of a sudden they flop in phase two trials, probably some of that gets clawed back. It needs to actually work and like all of the promises that they may have to play out. But they have Novartis behind them to, you know, propel them through that. And it feels like a pretty standard playbook. So good stuff there. And in general, it's just like it's cool.

Anyone who's dealt with allergies either personally or with loved ones, it's always a hassle. You know, everyone has a story of like someone was on vacation. They got a drink that had a nut in it and someone, you know, had an allergic reaction. And anything that can treat that is obviously good. good. So another arrow in the quiver of modern medicine, which is great to see. Breaking news, huge leak. OMG, did you guys know that Anthropic was training a better model this whole time? This is shocking, according to unemployed capital allocator. Of course, referencing a leak, a scoop.

I wonder if this will trigger the team of deep mind or open AI to consider training a better model. It feels like if they're doing, they're going to have to respond. So you could see multiple companies training new models based on this leak. Yeah. Yeah, an interesting story. There's some interesting. It's more from a marketing perspective and how you actually roll out and manage like vibes and yeah. To me, to me it doesn't seem improbable that there's been a lot of spud talk sure on the timeline this week. You got to get you got to start pumping mythos. Mythos talk. The most powerful AI model ever developed. It's a good tagline. And very, very painful for all the SaaS companies out there that just sell off whenever Anthropic does something.

And it's a vicious cycle now. Prince wrote a little summary of this. Anthropics has been testing a new model called Mythos with certain customers. They call it a step change in AI capabilities, including dramatically higher scores, encoding academic reasoning and cybersecurity. I want to know how it will do an ARCGIV3 because all of the models are under 1% completion on that benchmark. It's the one benchmark that is not saturated. It's not, it's very closely guarded. You can't get into the test set, the actual test set. You can only see the examples. And it clearly is, I still love the benchmark and the team over at Arc for what

they're doing. So this is part of a new Capibara series of models, which are largely, larger and more intelligent than Opus. It's more expensive to run. And it's not ready yet for general release, but they are excited about it. Mythos pricing bets coming in from 0.005 seconds, $100 in 250 out. Subs reprice to $50, $250, and a $1,000 plan might be coming. Who knows, what do you think? Well, let's pull up this picture of a Capi Bar just to put this into context. Is it a mythical creature?

No, Capi Barra is real. So what's the connection between Papi Bar and Mythos? Quite docile. Okay. But they can get violent. Let's look at this picture. Okay, watch out. I mean, look at the, look at the chomp on that.

This is something we should read into. We should say, what are, what did they mean by this? You know, it's clearly some sort of vague post. They're telling you, they're telling you something that, you know, friendly, cute, but also potentially the end of the world. Do you think we could contain it? Do you think if we had one in the studio, it would overrun us? or do you think we could keep it locked up?

I think... That's pretty horrifying. I think four or five of these could take you down. Median weight is between 60 and 174 pounds. 174 pounds. That's a... That's bigger than my dog. Wow.

That's a big... That's what I'm saying. They have these at the Santa Barbara do. So this is the metaphor. You know, like, these models are getting incredibly powerful. You need to contain them and think about safety, and you need to think about how do you keep the capy bar safe? you need to lock it in a box in a cage.

It cannot be allowed to run free. Yeah, I think just back on the pricing thing, I think like this is generally right. So basically 0.005 seconds is saying like it's just going to get 10x more expensive. Because right now I think it's something like $10 in, 25 times out. People are ready for people are ready to pay more though. Like they're paying a bunch through the API. They're paying more in cursor.

The subscription, like technically it's the same price, but the limits are going down. So it's okay. The tokens are getting more expensive. Yeah. And as you see, like, there's like this insane compute crunch. Like, I assume that models are going to get much more expensive as they're getting bigger. Yeah, it is interesting. I wasn't expecting to be in the regime of, like, subscriptions as long as we have been.

Like, just talking to Ben on our team about how he sort of bounces around from one subscription to the next. Like, he'll max one out and then move over to the next one and then move over to the different one. And he's, he's like maybe more price sensitive than model sensitive. I would always assume, I'd always assume that most businesses would just be on an API consumption basis. So the reason, like, I'm not hitting the APIs is because it's, it is like basically 10x more expensive. It's more expensive, yeah. Then using the subscription. The subscription.

So you do most of the work in the subscription, which is just, I mean, that's economically rational. I guess what I'm saying is, like, I'm surprised by how many people who are in a business context still make that decision and how much of a price war we're in, how much capital matters. Well, let's pull up this video because I'm not sure, I'm not sure you guys would be making the same decisions with the Capybara family of models if you knew that Capi Baras were capable of this kind of thing. They can swim? Wait, this is a human. Is this AI? Oh my God.

That's really attacking her. Wow. This is why they're calling it their most powerful model ever. We need to slow down. We need to slow down with the- All right, we can turn it off. It's horrifying. It's horrifying.

Yeah, we need to slow down. I hope they, you know, keep this with the safety team for long. I think we need all countries to come together and agree to control the Capibara population because that is truly horrifying. Take him has a very independent take. He's the biggest NVIDIA stand, and he makes a lot of good points. But he's making the argument that Anthropic needs more GPU. because he's sharing some posts here.

To manage growing demand for Claude, we're adjusting our five-hour session limits for free pro max subs during peak hours. Your weekly limits remain unchanged. And take him is coming on the show Monday. I'm very excited to talk to him. Well, ask him what he thinks about Nvidia. Yes.

And so a lot of people are getting into polyphasic sleep because of this. So Claude has different limits at different times. So when the limits are in effect, that's when you need to be sleeping. Tyler, have you gotten into polyphasic sleep yet? I'm not there yet, but I mean, the problem is getting worse. Okay.

I think at some point I'm going to ask you. I told Tyler that sometimes I indulge in polyphasic sleep after the show. I'll sleep for an hour and then I'll go about my day and then I'll sleep at night. And he said that's just a nap. It doesn't count. I guess people really are doing the polyphasic sleep thing to monitor their agents. You would think you would know one person that has done that and stuck with. it because I feel like a bunch of people have tried that over time.

Yeah. And then eventually... I mean, if you're trying to get around the limits, polyphysic sleep doesn't make sense. You just need to basically be nocturnal, right? Because you need to be like inverse what like San Francisco hours are, right? Yeah. So the peak, San Francisco usage, you gotta be like... Yeah, or just move overseas.

You could do that. Yeah. But the polyphazic sleep doesn't really help, right? No. No. It seems like it's much better to just, again, you know, have a compute desk or a, or a prompt desk that is geographically distributed evenly across the globe. So when your American employee stops the prompting, goes home for the night,

then your European colleague steps up and starts prompting on the same project, and then your colleague in Asia can pick up when Europe goes to bed, something like that. You know what I mean? So you have 24-7 coverage. Yeah, but that's still like at, during one of those periods, it's still like the peak hours, right? Yeah, yeah, because these peak hours are based around U.S. hours. I was more, so there's actually two things going on.

There's one where it's like you're waiting for your agents to respond, and if it's going to take hours for a prompt to return, you should go take a nap because you're better off checking in on a prompt every two hours for the whole day, for 24 hours in perpetuity, as opposed to doing, you know, a two-hour prompt, watching TV, come back, do that eight times, and then sleep for eight hours. That's four more two-hour sessions that you could have been letting it cook and, like, interacting with it. That's separate from trying to get around these rate limits. Last March, like a year ago, people were like $50 billion, $100 billion, $200 billion, is this stuff that useful?

Is it slop? Is it actually going to be that useful? Are these things toys? Like, yeah, they're reasonable for this thing, but what's the real economic value? Certainly it can't be more than like 20 bucks a month or $200 a month. And now there's like lots of people that are maybe they're only paying a few thousand a month because they're using a bunch of subscriptions, but like they're pretty close to justifying like the Jensen like 250K a year per engineer thing. Like that doesn't feel that far away from companies just saying like, yes, I, I, I, I, I, I, I, I, I, I, I give you the permission to spend $250,000 a year on AI inference. Be as efficient as possible as you can with that budget, but you have my approval. I believe that with that $250, you will generate more than that in value. Yeah, I think the big thing is like there's going to be more use cases that have a similar level of product market fit as Kodgen that use tokens on the level

that these code gen tools do. Yeah. And we haven't fully identified those yet. There's some early evidence that just like general agents. Yeah. We'll drive that. But like I would say, an example is like, it seems very obvious that models will be very useful for making financial models.

But do you need to make 500 financial models per day? No. Right? Yeah, that is interesting. And so there are areas where the models are going to be incredibly, incredibly valuable, incredibly important, used by everybody in any given field, and yet they won't necessarily generate. There are some people that would need to make 500 financial models a day.

Like, I think Rokana makes, like, hundreds of trades every single day. And so if you're doing a proper, like, full DCF, pulling every SEC filing for a company, and you're doing that hundreds of times a day because you're trading. Or he might have hundreds of individual positions. Exactly. And you want real-time models. Sort of like rebuilding a Bloomberg terminal for yourself. I think he needs, I think Bloomberg exists and maybe should work there.

The news is that Anthropic has been granted a preliminary injunction, the Pentagon supply chain risk designation in California, but is allowing stay for one week. I think a lot of people, like the tech community broadly, came away with this prediction that this wouldn't hold that this was, you know, whatever you thought about how you work with the government and the Ben Thompson thesis, there was, you know, the supply chain thing wasn't really going to stick.

It wouldn't necessarily hold up in court, but we'll see where it goes. Dean Ball says this is a devastating ruling for the government, finding Anthropic likely to prevail on essentially all of its theories for why the government's actions were unlawful and unconstitutional. One of the things she mentions is the huge range of Amici briefs. I don't know how to say Amici briefs supporting Anthropic, by way, zero a half. Hey, finally, a week. word that John can't nail instantly.

You have an incredible mind that we did find. We found my limit. We found my limit. On a personal note, says Dean Ball, some friends and allies of mine on the right who have been angry at me for my own words and actions and all of this,

anyone who thinks I spoke out for personal gain or trivial reasons against an administration I served in is crazy. Yeah, people forget that Dean Ball served not in the first Trump administration, but the second Trump administration. And he was like, Look, I wrote the AI policy thing.

I worked on that. Like, this is not the right path. So it's a meeky. It's the plural of amicus. This is brutal for me because I studied Latin. And I should be able to nail this because I know it's a Latin word. Anyway, it was a hugely costly decision for Dean Ball. But this judge's ruling shows why I did it.

This is a staggeringly illegal act by the government. That is why I'm particularly honored to have been implicitly quoted in the ruling for calling this what it was. when Secretary Hegeseth made his initial announcement an attempted act of corporate murder. He's standing with the corporations. This case continues, but Anthropic has scored a very large win here. The real victors, however, are all red-blooded Americans who are, as the founders would have said, jealous of their liberties. I love it.

Well, congratulations. And hopefully, everyone can just go back to building good models. You know, all this nonsense in D.C. has been a huge, huge side show, side project, side quest, as the race for compute is so much more important. The race for capabilities is so much more important. The other scoop is coming from Axios. Sam Altman apparently told staff he tried to save Anthropic in the Pentagon Clash, which he apparently thought was somewhat ironic given that said competitor openly,

openly blasted him on any podcast that they go on. Last Anthropics story, IPO. They're trying to go public as early as Q4 with a potential 60 billion raise. They're racing. And so let's go over to Kalshi and see who is likely to announce an IPO this year. Anthropics up at 70% on this news. They jumped up from 46% to over 70%. Opening eyes at 49%.

Jersey Mike's still beating them both, 75%. So you Jersey Mike's heads out there. They do very well in the app store. I like the sandwiches. SpaceX is in 94. Discord is also sitting at 63%. Oh, Discord. What a crazy story.

I love Jason Citrin so much, the founder. But he is out, I think. And he has just a wild, wild founder story. I made a whole video about it. It's a lot of fun. We got to hit the mansion section. One last note on AI. Before we move on to the really important thing,

real estate. Open AI has surpassed $100 million an annualized run rate. 100 million. It's pilot. Yeah. Launched six weeks ago. It's expanded to 600 advertisers and plans to launch self-serve advertiser access in April.

I am close to setting up a new account and or just churning momentarily so that I get to experience the ads. You know I love ads. I mean, the first ad being for the Wall Street Journal that we know and love is a very good omen. Clearly something's going on. They're happy with each other because they're working together. Yeah. I mean, truly like the alpha for the audience. is like new ad platforms often deliver really good results before people figure them out.

Big companies move slower than you. If you can be the first person to advertise, figure it out, you know Sean Frank at the Ridge is thinking about it, and maybe you should be too. Not to do an ad for ads, but we love ads on the show and we love new ad platforms. What's this news before we go on? Apple's talking about opening up Siri to rival AI services? Weird. I don't know.

I'm going to guess the Germanator. That's right. Of course. Apple plans to open Siri to outside AI assistance as part of a Siri overall. Do we need to give him the golden scoop? Tyler, hold up the Golden Scoop Award for Mark German. The Germanator has received the Golden Scoop Award for March 27, 2026. Congratulations, Mark German.

It is an honor. Your scoop wins the golden scoop of the day. There we go. Yeah, the scoop. That's good. Scoop, scoop, scoop, scoop, scoop, scoop, scoop. Scoop, scoop, scoop, scoop, scoop, scoop, scoop, scoop, there it is. Scoop, there it is.

Things like chat, GPT, Emini, et cetera, could be allowed to effectively take the place of Siri. The company is developing new tools to allow AI chatbots installed via the App Store to integrate with the Siri assistant, enabling users to send queries to services like LLMs. The change is part of an attempt to turn around Apple's fortunes in AI, where it is lagged behind Silicon Valley Peers and could allow Apple. to generate more money from third-party AI subscriptions through the App Store. Oh, yeah, because you upgrade through there. That would be good. I think that's part of it. I think there's also the antitrust angle, which is that they have had to allow you to change the default search engine in Safari for a while, even though they have that relationship with Google.

When you go to the Safari search bar and you just type in some random words, it searches Google. You can actually reroute that to ChatGPT. I did it. ChatTPD is like, I don't use it like I use Google. Google I use for like really, I want like a five millisecond query. So the time to actually load ChachyPT and then give you the full answer was not the best experience. But I have wanted for a long time to reroute the Siri button on the side of the phone to just ChachypT instant fast, ultra fast, just talk to me. But every time I do it, I say, Chachypti, what's the history of the Roman Empire? And it loads and it says working with Chachypti and then it like takes a little bit too long. and then you get like a short note and then you can open it and it just sort of like you're always fighting in the UI between like are you talking to Apple Intelligence or are you talking to Siri or are you talking to chat GPT and you sort of go back and forth so we will see where this goes if I would be very surprised if people shipped away from the default like if if Apple iPhones ship with the Siri button just querying their distilled

Gemini model or whatever they're going to wind up doing there that's probably what most people are going to use but it's exciting that at least there will be some competition in the market. Barry Diller just paid $11 million for JFK's favorite New York penthouse, not favorite new. An entity linked to the billionaire purchased Karen Pritzker's co-op at the Carlisle, the same unit where Kennedy famously stayed during his visits to the city. In the 50s and 60s, John F. Kennedy stayed in a duplex penthouse at the Carlisle Hotel so often that it became known as the New York White House.

after his assassination, his widow and two children, Caroline and John Jr., lived in the Manhattan Hotel for about 10 months. What's the longest amount of time you've ever spent in a hotel? I don't think I've ever done more than like a week or two. Ten months is a, that's a run. Yeah, I never, I never went through an era of my young adulthood. That's like sort of a crazy move. That I could, could have afforded to stay in a hotel permanently.

Yeah. But now that I'm a, now that I'm a, you know, I was walking in some hotel the other day. And I was like, I wonder if I could like live here. It just doesn't, it's just like with kids. Yeah, it would just be bad. Anyway, now an entity linked to billionaire Barry Diller has purchased Kennedy's favorite penthouse for $11 million. Diller bought the co-op unit from another family of prominent Democrats. Film producer Karen Pritzker and heiress to the Hyatt Hotel Fortune bought the apartment for $12 million in 2007.

Pritzker put the apartment on the market for $12.9. for 12.5 in 2007. The Carlisle opened around 1930 on Manhattan's Upper East Side, one of New York's most storied luxury hotels. It's known for iconic venues like Bemelins Bar, Cafe Carlisle, a cabaret space that has hosted legendary performers. A portion of the building was converted to co-op units decades ago. Kennedy stayed at the hotel so often, starting when he was still a senator in the 1950s, that a direct phone line was installed for him in his regular duplex suite. That's cool. After his assassination, Jacqueline Kennedy moved to the hotel but stayed in a different suite. On rainy days, the Kennedy children played in the lobby. The two-bedroom

apartment includes a large foyer with an Art Deco staircase. The listing says, an expansive corner living and dining room has views over Central Park. There's also a bookshelf-line breakfast room and a corner salarium with a wet bar. Oh, speaking of wet bars, forget Aprae Ski because homeowners are now building their own bars in custom spaces where they can relax and get toasty after a day on the slopes. This is also from the mansion section in the old journal today. For Brian Healy, what comes after a day on the mountain sometimes takes precedence over the skiing itself.

When he built his Lake Tahoe area vacation home in 2019, he spent about $800,000 to build a bar area on the main floor of the house. Well, that's an absolute dog. Which he can ski to from the slopes. It's pretty good. North Star. That's bad. Sounds great. So maybe not ski in, but ski out.

Yeah. He said, I've joked that I designed a bar and built a house around it. This is good. This is my dream. I'm going to build a movie theater and then build a house around it. That's my goal. What would yours be? John was sending me a listing. Bull surfing ability,

one of those endless waves. That's what you need. You need an endless wave pool. You know what I'm talking about? What are those called? Wave pools. Wave pool? Yeah, full wave pool? Yeah. Wait, why are you not excited about this prospect of having a house that's built around this endless wave pool? Is there some drawback?

I live in... Oh, I guess you just go to the ocean. Yeah, you could just go... You could just be walking distance from the beach. Anyway, it's hard to be. Healy 51 is an Ireland native. Let's go. Let's hear it for Ireland.

He runs an energy company in the San Francisco Bay Area. This is Royal Flash. You've got to meet this guy. After a day on the slopes, Healy and his pals head to the space, dubbed Healy's Bar, leaving their gear in the storage area of the Truckee, California property. And sometimes other skiers end up at Healy's home after getting lost while skiing through the trees. It's an open door policy. He says we invite them in for beer. This is our inn.

We need to head over to North Star and get lost and wind up at his bar. Oops. Uh-oh. We're lost. We don't know. I know some former guests that are neighbors. with this guy. Oh, yeah.

Any, uh... We'll work on connecting them. Could you spare Guinness for us for two Irish chaps who've gotten lost? I feel like I read like a children's story of like wandering in the forest and then like, you know, some character offers you something. Sometimes it's like that. Yeah, usually that can send you on kind of a crazy... Q1 of last year, Mark Zuckerberg texts Elon.

Looks like Doge is making progress. I've got our teams on alert to take down content doxing or threatening the people on your team. Let me know if there's anything else I can do to have to have. help. Elon reacted heart. And he says, are you open to the idea of bidding on the open AI IP with me and some others? Suck says, want to discuss live? Oh, interesting. And Matthew Zitland, former guest, says you can tell who is used to antitrust investigations. Well, stay safe out there. If you're planning on bidding for some IP and you're two of and you're chatting with the richest man in the world.

Yeah, maybe stick to a phone call. Who knows? We love to. Goodbye. Flashbang!